Abstract
As healthcare capacities in the US and Europe reach their limits due to a surge in the COVID-19 pandemic, both regions enter the 2020-2021 influenza season. Southern hemisphere countries that had suppressed influenza seasons provide a hopeful example, but the lack of reduction in influenza in the 2019-2020 influenza season and heterogeneity in nonpharmaceutical and pharmaceutical interventions show that we cannot assume the same effect will occur globally. The US and Europe must promote the implementation and continuation of these measures in order to prevent additional burden to healthcare systems due to influenza.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank Reseau Sentinelles and IQVIA France for providing us access to flu vaccine sale data. Research reported in this publication was supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number R01GM123007. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also acknowledge support from the PhRMA Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We revise this work to reanalyze the 2019-2020 influenza season. Analysis of influenza A separate from influenza B showed that influenza B experienced an atypical season, occurring much earlier and at higher levels than usual. Analyzing influenza A separately reveals that influenza A was not significantly different than expected based on prior years. With this new finding, we turn our attention to influenza throughout 2020 to assess how COVID-19 impacted influenza globally. We also add an ethics statement for use of the Safegraph dataset.
Data Availability
All data used in the study is publicly available and cited in the work
